Teymour Boutros-Ghali
Managing Partner @ Bold Capital Partners
Los Angeles, United States
Teymour Boutros-Ghali is a Series A investor at Bold Capital Partners in Los Angeles focused on Health Care and Medical. Teymour Boutros-Ghali has over the years established a successful track record as an investor and entrepreneur focused on the commercialization of disruptive technologies. His interests have ranged from the reshaping of the media landscape through technological innovation, to the ongoing rebirth of the enterprise through technology—driven strategicadvantage. He is co-founder of Bold Capital Partners and Monitor Ventures, two investment and advisory partnerships, and has also been a founder/executive of several successful technology start-ups.As Chairman of C Publishing, he oversees a successful group of luxury media properties. He was also a founder and CEO of All Business, a B2B web site targeted to small businesses (sold to GE-NBC); and, as part of his work on technology commercialization he served for several years as senior advisor to Interval Research, Paul Allen’s Silicon Valley incubator, as well as, more recently, designing Saudi Aramco’s corporate venture fund.Prior to his entrepreneurial activities, Teymour was an executive with Time Warner. Over a ten-year period, he held a number of positions, including: Vice President of Time Inc.’s corporate venturing arm, Time Inc. Ventures; and, Publisher of Time International—responsible for repositioning and running the media property worldwide.Before joining Time Warner, Teymour was a consultant with the Boston Consulting Group. He was a leader of the media and telecommunications practice and also served as head of recruiting for BCG.Teymour Boutros-Ghali holds an SM from the Sloan School of Management in Finance; a PhD from the Massachusetts Institute of Technology in theoretical Plasma Physics (his thesis dealt with the formation of coherent structures out of chaotic turbulent systems); and, a BA from Cambridge University in EE & CS. Teymour Boutros-Ghali sits on the board of several private companies, has lectured on entrepreneurship at the Anderson School of UCLA and been a judge for the annual Ernst & Young Entrepreneur of the Year Award.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Teymour Boutros-Ghali invests in
Stages Teymour Boutros-Ghali invests in
Countries Teymour Boutros-Ghali invests in
Investment Focus
Industry
- Health Care 3 (25%)
- Medical 2 (17%)
- Therapeutics 2 (17%)
- Biotechnology 2 (17%)
- B2B 1 (8%)
Stage
- Series A 5 (42%)
- Series B 2 (17%)
- Seed 1 (8%)
- Series C 1 (8%)
- Convertible Note 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Syntis Bio
|
Syntis Bio operates as a late-stage preclinical company intended to develop a new class of therapy. The company's drug uses novel formulations for oral therapies that target specific tissues, enabling users to increase bioavailability. | $33M / Series A / Jul 01, 2025 | |
Gallant
|
Gallant is developing a scalable stem cell therapy platform that will allow any veterinarian to routinely treat pets in a primary care setting, improving the lives of pets and their people. By systematically addressing challenges that previously hindered stem cell therapy adoption, the company aims to make stem cell products accessible in order toelevate the quality of life for all pets and the people that love them. | $18M / Series B / Mar 15, 2025 | |
Gallant Therapeutics
|
Gallant Therapeutics is an animal health biotechnology company developing allogeneic, "off-the-shelf" stem cell therapies from their stem cell platform. Gallant is also the leading provider of non-invasive stem cell banking during the spay or neuter process, opening the door to novel regenerative medical treatments formerly unavailablefor non-human family members. Clinical studies demonstrate stem cell therapies help pets with a multitude of ailments, including osteoarthritis, atopic dermatitis, chronic kidney disease, and chronic stomatitis, among others. Gallant's first product helps to save cats that would die of chronic gingivostomatitis, with a robust pipeline in development for companion animals. | $15M / Series A / Jan 08, 2024 | |
|
Gallant
|
Gallant is developing a scalable stem cell therapy platform that will allow any veterinarian to routinely treat pets in a primary care setting, improving the lives of pets and their people. By systematically addressing challenges that previously hindered stem cell therapy adoption, the company aims to make stem cell products accessible in order toelevate the quality of life for all pets and the people that love them. | $15M / Series A / Jan 08, 2024 | |
Viome
|
Viome is a provider of comprehensive health insights designed to help people track their microbiome health, mitochondrial health, cellular health, and biological age. The company's insights help users to make suitable lifestyle and nutrition choices for them, enabling users to assess their internal eco-system with simple personalizedrecommendations.Viome was established on October 1, 2016 by Naveen Jain in Bellevue, Washington. | $86.5M / Series C / Aug 18, 2023 | |
|
Viome
|
Viome is a provider of comprehensive health insights designed to help people track their microbiome health, mitochondrial health, cellular health, and biological age. The company's insights help users to make suitable lifestyle and nutrition choices for them, enabling users to assess their internal eco-system with simple personalizedrecommendations.Viome was established on October 1, 2016 by Naveen Jain in Bellevue, Washington. | $67M / Series C / Oct 11, 2022 | |
Crowdz
|
Crowdz is the leader in modernizing the traditional Trade Finance industry by auto risk rating assets at the receivable level. Funders can gain valuable insights to make quick decisions that match their investment strategy. Crowdz has auto risk-rated $4.2b of receivables, and funders have financed over $93m utilizing Crowdz technology. Customersand investors include Citibank, Barclays, Meta, EG Funds Management, Techstars Ventures, and Bold Capital Partners, with over $28 million in investment raised to date.Assets sold to private equity. | $10.1M / Convertible Note / Apr 26, 2022 | |
|
Crowdz
|
Crowdz is the leader in modernizing the traditional Trade Finance industry by auto risk rating assets at the receivable level. Funders can gain valuable insights to make quick decisions that match their investment strategy. Crowdz has auto risk-rated $4.2b of receivables, and funders have financed over $93m utilizing Crowdz technology. Customersand investors include Citibank, Barclays, Meta, EG Funds Management, Techstars Ventures, and Bold Capital Partners, with over $28 million in investment raised to date.Assets sold to private equity. | $14.7M / Series B / Apr 26, 2022 | |
|
Crowdz
|
Crowdz is the leader in modernizing the traditional Trade Finance industry by auto risk rating assets at the receivable level. Funders can gain valuable insights to make quick decisions that match their investment strategy. Crowdz has auto risk-rated $4.2b of receivables, and funders have financed over $93m utilizing Crowdz technology. Customersand investors include Citibank, Barclays, Meta, EG Funds Management, Techstars Ventures, and Bold Capital Partners, with over $28 million in investment raised to date.Assets sold to private equity. | $3M / Series A / Jun 30, 2020 | |
|
Crowdz
|
Crowdz is the leader in modernizing the traditional Trade Finance industry by auto risk rating assets at the receivable level. Funders can gain valuable insights to make quick decisions that match their investment strategy. Crowdz has auto risk-rated $4.2b of receivables, and funders have financed over $93m utilizing Crowdz technology. Customersand investors include Citibank, Barclays, Meta, EG Funds Management, Techstars Ventures, and Bold Capital Partners, with over $28 million in investment raised to date.Assets sold to private equity. | $7M / Series A / Jun 30, 2020 | |
| See all 12 investments → | |||
Co-Investors
Augment Ventures
5 deals together
Citi
3 deals together
Digitalis Ventures
3 deals together
Global Cleantech Capital
3 deals together
Kube VC
3 deals together
About Bold Capital Partners
Bold Capital Partners is an early-stage venture capital firm investing in life sciences, healthcare, and frontier tech companies.
Bold Capital Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Teymour Boutros-Ghali
Managing Partner
|
|||
Will Borthwick
Principal
|
|||
Emilio Diez Barroso
Partner
|
|||
Felicia Hsu
Investor
|
|||
Maxx Bricklin
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Teymour Boutros-Ghali invest in?
Teymour Boutros-Ghali invests primarily in Health Care, Medical and Therapeutics startups, most often at Series A and Series B stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Teymour Boutros-Ghali last invest?
The most recent investment recorded for Teymour Boutros-Ghali closed in Jul 2025. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
